Cencora, Inc. · NYSE:COR

Cencora — AmerisourceBergen — Q4 FY2017 Earnings Presentation

17 slides from Cencora's earnings presentation, Nov 2, 2017

  1. Slide 1: Q4 & Full Year FY2017 Financial Results

    Q4 & Full Year FY2017 Financial Results November 2, 2017

  2. Slide 2: Cautionary Note Regarding Forward-Looking Statements

    Cautionary Note Regarding Forward-Looking Statements Certain of the statements contained in this presentation are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as "expect," "likely," "ou

  3. Slide 3: AmerisourceBergen is creating healthier futures

    AmerisourceBergen is creating healthier futures • Shaping healthcare delivery through knowledge, reach and partnership • Providing industry leading services and solutions that improve product access, increase supply chain efficiency and enhance patient care 3

  4. Slide 4: Q4 and Full Year FY2017 Financial Results: Overview

    Q4 and Full Year FY2017 Financial Results: Overview ▪ AmerisourceBergen continues to execute and deliver in a dynamic healthcare market - Continued year-over-year revenue and EPS growth - Generics volume growth – significantly increased compliance across provider customer base - Continued to lead th

  5. Slide 5: Q4 FY2017 Financial Results

    Q4 FY2017 Financial Results Adjusted GAAP (Non-GAAP)1 Revenue $39.1B $39.1B % Change (Year-over-Year) 4.2% 4.2% Gross Profit $1.2B $1.1B % Change 4.2% 4.4% Operating Expenses $1.3B $626M % Change 39.7% 6.8% Operating (Loss) Income $(85)M $471M % Change (137.8)% 1.5% Interest Expense, Net $35M $35M %

  6. Slide 6: Full Year FY2017 Financial Results

    Full Year FY2017 Financial Results Adjusted GAAP (Non-GAAP)1 Revenue $153.1B $153.1B % Change (Year-over-Year) 4.3% 4.3% Gross Profit $4.5B $4.4B % Change 6.4% 1.1% Operating Expenses $3.4B $2.4B % Change 25.1% 2.7% Operating Income $1.1B $2.0B % Change (27.2)% (0.7)% Interest Expense, Net $145M $14

  7. Slide 7: Q4 FY2017 Financial Results: Pharmaceutical Distribution Services Segment

    Q4 FY2017 Financial Results: Pharmaceutical Distribution Services Segment Q4 FY2017 Q4 FY2016 Revenue $37.7B $36.3B Operating Income $399.7M $398.0M Percentages of Revenue Gross Profit 2.14% 2.16% Operating Expenses 1.07% 1.06% Operating Income 1.06% 1.10%  Large anchor customers continue to grow i

  8. Slide 8: Q4 FY2017 Financial Results: Other Businesses – Global Commercialization Services & Animal Health

    Q4 FY2017 Financial Results: Other Businesses – Global Commercialization Services & Animal Health Q4 FY2017 Q4 FY2016 Revenue $1.5B $1.3B Operating Income $71.7M $66.3M Percentages of Revenue Gross Profit 19.82% 20.19% Operating Expenses 14.97% 15.17% Operating Income 4.85% 5.02%  Other includes Wo

  9. Slide 9: FY2018: How AmerisourceBergen Will Drive Value

    FY2018: How AmerisourceBergen Will Drive Value Leverage Scale Enhance Access • Go-to-market strategy • Specialty leadership • Integrated approach • Grow customer share of wallet • Seamless customer • Deepen manufacturer relationships experience • Build across human & animal health Drive Performance

  10. Slide 10: FY2018 Financial Guidance

    FY2018 Financial Guidance1 Expectations on an Adjusted (Non-GAAP) Basis Revenue Growth 7% to 9% Diluted Earnings Per Share $5.90 to $6.15 Operating Expense Growth 4% to 6% Operating Income 3% to 5% Effective Tax Rate 32% to 33% Free Cash Flow $1.25B to $1.5B Capital Expenditures ~$325M Working Assum

  11. Slide 11: Appendix

    Appendix N) AmerisourceBergen’

  12. Slide 12: GAAP to Non-GAAP Reconciliations: Three Months Ended September 30, 2017

    Appendix AMERISOURCEBERGEN CORPORATION GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Three Months Ended September 30, 2017 Operating (Loss) Income Diluted Operating (Loss) Interest Before Income Income Tax Net (Loss) Earnings Per Gross Profit Expenses Income Expe

  13. Slide 13: GAAP to Non-GAAP Reconciliations: Three Months Ended September 30, 2016

    Appendix AMERISOURCEBERGEN CORPORATION GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Three Months Ended September 30, 2016 Diluted Operating Operating Interest Income Before Income Tax Earnings Per Gross Profit Expenses Income Expense, Net Income Taxes Expense Ne

  14. Slide 14: GAAP to Non-GAAP Reconciliations: Fiscal Year Ended September 30, 2017

    Appendix AMERISOURCEBERGEN CORPORATION GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Fiscal Year Ended September 30, 2017 Diluted Operating Operating Interest Income Before Income Tax Earnings Per Gross Profit Expenses Income Expense, Net Income Taxes Expense Net

  15. Slide 15: GAAP to Non-GAAP Reconciliations: Fiscal Year Ended September 30, 2016

    Appendix AMERISOURCEBERGEN CORPORATION GAAP TO NON-GAAP RECONCILIATIONS (in thousands, except per share data) (unaudited) Fiscal Year Ended September 30, 2016 Income Tax Diluted Operating Operating Interest Income Before (Benefit) Earnings Per Gross Profit Expenses Income Expense, Net Income Taxes E

  16. Slide 16: Reconciliation of Diluted Weighted Average Common Shares Outstanding

    Appendix AMERISOURCEBERGEN CORPORATION RECONCILIATION OF DILUTED WEIGHTED AVERAGE COMMON SHARES OUTSTANDING (GAAP TO NON-GAAP) (In thousands) (unaudited) Three Months Ended September 30, Fiscal Year Ended September 30, 2017 2016 2017 2016 Basic shares outstanding 218,501 219,087 218,375 212,206 Stoc

  17. Slide 17: AmerisourceBergen: Where knowledge, reach and partnership shape healthcare delivery

    N) AmerisourceBergen’ Where knowledge, reach and partnership shape healthcare delivery.

AmerisourceBergen — Q4 FY2017 Earnings Presentation on 6ix